Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in ...
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results